Altium Capital Management LLC Has $6 Million Stock Position in Glaukos Co. (NYSE:GKOS)

Altium Capital Management LLC trimmed its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 48.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,000 shares of the medical instruments supplier's stock after selling 37,000 shares during the period. Glaukos makes up about 1.7% of Altium Capital Management LLC's portfolio, making the stock its 19th biggest position. Altium Capital Management LLC owned about 0.07% of Glaukos worth $5,998,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. CANADA LIFE ASSURANCE Co raised its stake in Glaukos by 0.9% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 64,929 shares of the medical instruments supplier's stock worth $9,751,000 after purchasing an additional 601 shares during the period. Farringdon Capital Ltd. purchased a new position in Glaukos in the fourth quarter worth approximately $244,000. Evergreen Capital Management LLC lifted its position in shares of Glaukos by 5.4% during the 4th quarter. Evergreen Capital Management LLC now owns 3,472 shares of the medical instruments supplier's stock worth $521,000 after purchasing an additional 177 shares during the last quarter. Barclays PLC increased its holdings in shares of Glaukos by 2.3% in the 4th quarter. Barclays PLC now owns 91,785 shares of the medical instruments supplier's stock valued at $13,762,000 after acquiring an additional 2,086 shares during the last quarter. Finally, Summit Investment Advisors Inc. raised its holdings in Glaukos by 3.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,007 shares of the medical instruments supplier's stock worth $751,000 after purchasing an additional 145 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Stifel Nicolaus increased their price objective on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Needham & Company LLC boosted their price target on Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Mizuho dropped their target price on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Wednesday, April 16th. Piper Sandler dropped their price objective on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research report on Tuesday, April 15th. Finally, Wells Fargo & Company increased their price objective on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $156.17.

Glaukos Stock Performance

Shares of NYSE:GKOS traded up $2.60 during trading hours on Wednesday, hitting $92.33. The stock had a trading volume of 341,709 shares, compared to its average volume of 639,592. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The stock's fifty day simple moving average is $105.86 and its 200 day simple moving average is $130.82. The firm has a market capitalization of $5.22 billion, a price-to-earnings ratio of -32.17 and a beta of 0.88. Glaukos Co. has a 1-year low of $77.91 and a 1-year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Sell-side analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.